| Prev Close | 1.49 |
| Open | 1.50 |
| Day Low/High | 1.44 / 1.54 |
| 52 Wk Low/High | 1.01 / 5.15 |
| Volume | 574.76K |
| Avg Volume | 929.00K |
| Exchange | NASDAQ |
| Shares Outstanding | 45.76M |
| Market Cap | 68.18M |
| EPS | -0.70 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
April 2017 Options Now Available For Alimera Sciences (ALIM)
Investors in Alimera Sciences, Inc. saw new options become available today, for the April 2017 expiration.
Alimera (ALIM) Is Today's Strong On High Volume Stock
Trade-Ideas LLC identified Alimera (ALIM) as a strong on high relative volume candidate
Weak On High Volume: Alimera (ALIM)
Trade-Ideas LLC identified Alimera (ALIM) as a weak on high relative volume candidate
Insider Trading Alert - VLGEA, LLTC And ALIM Traded By Insiders
Stocks with insider trader activity include VLGEA, LLTC and ALIM
Short Interest In Alimera Sciences Makes 15% Move
The most recent short interest data has been released by the NASDAQ for the 01/29/2016 settlement date, which shows a 314,613 share increase in total short interest for Alimera Sciences, Inc. , to 2,422,062, an increase of 14.93% since 01/15/2016.
Short Interest In Alimera Sciences Jumps 14.2%
The most recent short interest data has been released by the NASDAQ for the 01/15/2016 settlement date, which shows a 261,657 share increase in total short interest for Alimera Sciences, Inc. , to 2,107,449, an increase of 14.18% since 12/31/2015.
Short Interest In Alimera Sciences Decreases By 17.4%
The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 387,663 share decrease in total short interest for Alimera Sciences, Inc. , to 1,845,792, a decrease of 17.36% since 12/15/2015.
Alimera Sciences Announces ILUVIEN® J Code J7313 Is Now Active
The CMS reimbursement code for ILUVIEN® is expected to ease and speed insurance payments
Alimera Sciences Announces New 36-Month Analysis That Shows ILUVIEN® Slows Diabetic Retinopathy Progression
Data presented as Late Breaking Development during Retina Subspecialty Day at AAO 2015
Alimera Sciences To Speak At Ophthalmology Innovation Summit 2015
Dan Myers, CEO, will join leading innovators in ophthalmology to discuss ILUVIEN® and advancements in the industry
